Johnson & Johnson to Build $1 Billion Cell Therapy Manufacturing Facility in Pennsylvania

Johnson & Johnson is investing more than $1 billion to build a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. The new facility will be located on Sumneytown Pike in the Spring House section of Lower Gwynedd Township and will expand the company's capacity to make cell therapy treatments for cancer and other diseases.

The pharmaceutical company says the facility will replace an existing building on the site. The CEO stated that what the company is building is manufacturing excellence and hope, noting that for someone facing cancer, weeks can feel like years.

The new investment will bring more than 500 biotechnology jobs over the next 12 years. The project is expected to create more than 4,500 jobs once operational.

Governor Josh Shapiro was present for the announcement, saying it reinforces his administration's commitment to supporting the life sciences industry. A county commissioner shared how the life sciences sector is growing for Montgomery County.

The $1 billion facility is part of a wider $55 billion investment plan by Johnson & Johnson to bolster its U.S. operations, unveiled last March. The plan includes a pledge to construct three new domestic manufacturing sites and expand others in the company's existing drug and medtech network. The company is also planning a new drug product manufacturing facility in North Carolina.

Johnson & Johnson did not lay out a timeline for the plant's expected completion. The company also did not specify the types of cutting-edge cell therapy technologies it plans to employ at the new site.